Deals In Depth: May 2011
Executive SummaryWith a three-way tie, deals by Glenmark/Sanofi, Elan/Proteostasis, and Mundipharma/Allos were each valued at $50 million. Takeda expanded into Europe and emerging markets through its $14 billion buy of Nycomed, while PE firm Cinven scored big when it sold IVD investment Phadia to Thermo Fisher Scientific for $3.5 billion. Shanghai Pharma's $1.9 billion IPO on the Hong Kong Stock Exchange pushed biopharma financing in May up to $2.8 billion. Late VC financings in the device sector made up the majority of fundraising, which totaled $469 million.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.